Squarepoint Ops LLC Decreases Stock Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Squarepoint Ops LLC reduced its position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 85.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 30,991 shares of the company’s stock after selling 175,425 shares during the period. Squarepoint Ops LLC’s holdings in Tenaya Therapeutics were worth $44,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Commerce Bank purchased a new position in Tenaya Therapeutics in the 4th quarter worth approximately $29,000. Mariner LLC purchased a new position in Tenaya Therapeutics in the 4th quarter worth approximately $30,000. Ground Swell Capital LLC purchased a new position in Tenaya Therapeutics in the 4th quarter worth approximately $32,000. Hsbc Holdings PLC purchased a new position in Tenaya Therapeutics in the 4th quarter worth approximately $45,000. Finally, SG Americas Securities LLC raised its holdings in Tenaya Therapeutics by 61.9% in the 4th quarter. SG Americas Securities LLC now owns 41,270 shares of the company’s stock worth $59,000 after acquiring an additional 15,777 shares during the last quarter. 90.54% of the stock is currently owned by hedge funds and other institutional investors.

Tenaya Therapeutics Trading Up 0.7%

NASDAQ:TNYA opened at $0.69 on Wednesday. Tenaya Therapeutics, Inc. has a 12 month low of $0.36 and a 12 month high of $4.06. The company has a market cap of $112.32 million, a PE ratio of -0.48 and a beta of 2.91. The company has a 50 day simple moving average of $0.47 and a two-hundred day simple moving average of $1.11.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.06). Research analysts forecast that Tenaya Therapeutics, Inc. will post -1.35 earnings per share for the current year.

Analyst Ratings Changes

TNYA has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Tenaya Therapeutics in a report on Friday, April 25th. Canaccord Genuity Group cut their target price on shares of Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, March 13th. Morgan Stanley cut their target price on shares of Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday, March 12th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $9.00 target price on shares of Tenaya Therapeutics in a research report on Friday, May 9th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $6.25.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.